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TRANSPLANTATION
Enhancement of G-CSF–induced stem cell mobilization by antibodies against
the 2 integrins LFA-1 and Mac-1
Gerjo A. Velders, Johannes F. M. Pruijt, Perry Verzaal, Ronald van Os, Yvette van Kooyk, Carl G. Figdor,
Evert-Jan F. M. de Kruijf, Roel Willemze, and Willem E. Fibbe
The 2 integrins leukocyte function anti-
gen-1 (LFA-1, CD11a) and macrophage
antigen-1 (Mac-1, CD11b) have been re-
ported to play a role in the attachment of
CD34 cells to stromal cells in the bone
marrow. When administered prior to inter-
leukin-8 (IL-8), anti–LFA-1 antibodies com-
pletely prevent the IL-8–induced mobiliza-
tion of hematopoietic stem cells in mice.
Here, we studied the role of anti-2 inte-
grin antibodies in granulocyte colony-
stimulating factor (G-CSF)–induced mobi-
lization of hematopoietic progenitor cells.
Administration of antibodies against the
 chain of LFA-1 or against the  chain of
Mac-1 followed by daily injections of G-
CSF for more than 1 day resulted in a
significant enhancement of mobilization
of hematopoietic progenitor cells when
compared with mobilization induced by
G-CSF alone. Also, the number of late
(day 28) cobblestone area–forming cells
in vitro was significantly higher after mo-
bilization with anti–LFA-1 antibodies fol-
lowed by 5 g G-CSF for 5 days than with
G-CSF alone (119  34 days vs 17  14
days), indicating mobilization of repopu-
lating stem cells. Pretreatment with block-
ing antibodies to intercellular adhesion
molecule-1 (ICAM-1; CD54), a ligand of
LFA-1 and Mac-1, did not result in an
effect on G-CSF–induced mobilization,
suggesting that the enhancing effect re-
quired an interaction of the 2 integrins
and one of their other ligands. Enhance-
ment of mobilization was not observed in
LFA-1–deficient (CD11a) mice, indicating
that activated cells expressing LFA-1 me-
diate the synergistic effect, rather than
LFA-1–mediated adhesion. (Blood. 2002;
100:327-333)
© 2002 by The American Society of Hematology
Introduction
Mobilization of hematopoietic stem cells and progenitor cells is a
property of a variety of cytokines. These include growth factors and
chemokines such as granulocyte colony-stimulating factor (G-
CSF),1-4 granulocyte-macrophage colony-stimulating factor (GM-
CSF),5 stem cell factor,6 flt-3 ligand,7,8 interleukin-1 (IL-1),9 IL-3,10
IL-8,11,12 and thrombopoietin,13 either administered alone or in
combination.14-16 The kinetics of stem cell mobilization induced by
the various growth factors may vary substantially. For instance,
flt-3 ligand induces mobilization in mice in 7 to 10 days,7 whereas
the chemokine IL-8 induces mobilization within 30 minutes.11
Over the past 5 to 10 years G-CSF has emerged as the most
widely used mobilizing agent in clinical studies employing stem
cell mobilization.4,17 Despite its widespread clinical application,
little is known about the mechanisms underlying G-CSF–induced
stem cell mobilization.
Adhesion molecules play an important role in the interactions
between hematopoietic progenitor cells (HPCs) and the bone
marrow microenvironment.18-22 Among these, the 1 and 2
integrins are involved in the cellular interactions between HPCs,
stromal cells, and the extracellular matrix.19 It has been shown that
the 1 integrins very late antigen 4 (VLA-4; CD49d) and VLA-5
(CD49e) are expressed on colony-forming HPCs and stem cells.20-23
The ligands for these integrins, vascular cell adhesion molecule-1
(VCAM-1) and fibronectin, respectively, are expressed on cells of
the bone marrow microenvironment.20,21,24 Their function in retain-
ing the HPCs in the bone marrow is supported by the observation
that in vivo administration of antibodies to VLA-4 and to its ligand
VCAM-1 induces mobilization of HPCs in mice and primates.25,26
The 2 integrins leukocyte function antigen-1 (LFA-1) and
macrophage antigen-1 (Mac-1) have been reported to play a role in
the attachment of CD34 cells to stromal cells through one of their
ligands, intercellular adhesion molecule-1 (ICAM-1), and through
heparan sulfate.18,26,27 Studies in our laboratory and by others have
shown that the 2 integrin LFA-1 is not expressed on murine
HPCs.28,29 In contrast to anti–1 integrin antibodies, antibodies to
the 2 integrins were unable to mobilize progenitor cells into the
bloodstream in mice and primates.24 When administered prior to
injection of IL-8, anti–LFA-1 antibodies completely prevented
IL-8–induced mobilization of hematopoietic stem cells.30
Because of the role of 2 integrins in the adhesion of murine
HPCs in the bone marrow and the inhibitory effect of anti–LFA-1
antibodies on IL-8–induced mobilization, we studied their role in
G-CSF–induced stem cell mobilization. In this study we found that
administration of antibodies to the 2 integrins LFA-1 and Mac-1
synergistically enhanced G-CSF–induced mobilization. In LFA-1–
deficient mice, G-CSF–induced mobilization was not enhanced when
compared with wild-type littermate controls. This suggests that the
synergistic effect of administration of anti–LFA-1 antibodies on
G-CSF–induced mobilization is not mediated by blocking of LFA-1–
mediated adhesion but is due to activating cells expressing LFA-1.
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Materials and methods
Animals
Male BALB/c mice with an age ranging between 8 and 12 weeks were
purchased from Broekman BV (Someren, The Netherlands). Animals were
fed commercial rodent chow and acidified water ad libitum. Heterozygous
LFA-1–deficient (CD11a) C57Bl/6J mice were a kind gift from Dr T.W.
Mak (Amgen Institute, Ontario Cancer Institute, Department of Immunol-
ogy and Medical Biophysics, Toronto, Ontario, Canada). Homozygous
CD11a-deficient mice were bred at the animal facility of TNO Laboratories
(Leiden, The Netherlands).
Cytokines
Recombinant human G-CSF (filgrastim, Neupogen, Amgen, Thousand
Oaks, CA; a kind gift from Amgen, Breda, The Netherlands) was diluted to
the desired concentration in endotoxin-free phosphate-buffered saline
(PBS) containing 0.1% bovine serum albumin and administered as an
intraperitoneal injection.
Monoclonal antibodies
For in vivo injection, rat antimurine monoclonal antibodies directed against
the following adhesion molecules were used: H154.163 (neutralizing
anti-CD11a, LFA-1, immunoglobulin G2a [IgG2a], kindly provided by Dr
M. Pierres, Centre d’Immunologie, Marseille, France31), H155.78 (non-
neutralizing anti-CD11a, LFA-1, IgG2a), 5C6 (neutralizing anti-CD11b,
Mac-1, IgG2b, kindly provided by Dr M. Robinson),32 and YN1/1.7
(anti-CD54, ICAM-1, IgG2b).33 Endotoxin testing was done on the
antibody to Mac-1. The endotoxin levels were 2.6 IU/mL as measured by
the Limulus amoebocyte lysate assay. This concentration of endotoxin is
not expected to have any effect on the mobilization of hematopoietic stem
cells into the peripheral blood of mice.34
Preparation of cell suspensions
Mice were killed by CO2 asphyxiation. Peripheral blood was drawn by a
cardiac puncture, and white blood cell counts were performed on a Sysmex
F800 (TOA Medical Electronics, Kobe, Japan). Manual neutrophil counts
were performed after May-Gru¨nwald Giemsa (MGG) staining of the
peripheral blood. Mononuclear cell suspensions were obtained after Ficoll
separation as described.9 The bone marrow cells were removed from the
femur by flushing the femur under sterile conditions with RPMI 1640
containing 500 g/mL penicillin, 250 g/mL streptomycin, and 2% fetal
bovine serum (GIBCO, Grand Island, NY) and 6% heparin (400 IU/mL).
All cells were washed twice in RPMI 1640 containing penicillin, streptomy-
cin, and fetal bovine serum in the concentrations as described.
Progenitor cell assays
Granulocyte macrophage colony-forming units (CFU-GMs) were cultured
as described previously.9 Briefly, peripheral blood mononuclear cells were
cultured in 3.5-cm dishes containing 5  105 cells per milliliter in semisolid
medium in the presence of recombinant murine GM-CSF (1.25 ng/mL;
kindly provided by Dr E. Liehl, Novartis Forschungsinstitut, Vienna,
Austria). Bone marrow cells were cultured in a concentration of 1  105
cells per milliliter. After 6 days of culture in a fully humidified atmosphere
of 37°C containing 5% CO2, the number of colonies, defined as an
aggregate of more than 20 cells, were scored using an inverted microscope.
FACS analysis
The number of mature neutrophils in blood and bone marrow was
determined by flow cytometry. Peripheral blood cells were lysed using
buffered ammonium chloride (NH4Cl 8.4 g/L, potassium bicarbonate
[KHCO3] 1 g/L, pH 7.4) and washed with PBS containing 0.8 g/L albumin
(CLB, Amsterdam, The Netherlands). The lysed peripheral blood cells and
the unlysed bone marrow cells were then incubated for 30 minutes at 4°C
with anti-CD3e and anti-CD45R/B220 antibodies—both phycoerythrin
(PE)-conjugated—and anti–GR-1 antibody conjugated to fluorescein isothio-
cyanate. After washing the cells were incubated at 4°C with Cychrome-
conjugated anti–Ly-5 antibody for 30 minutes (all rat antimouse monoclo-
nal antibodies were purchased from PharMingen, San Diego, CA). Then the
cells were washed again and then resuspended in PBS containing 0.8 g/L
albumin. To determine the morphology of the Gr-1 cells, cells were
fluorescence-activated cell-sorter (FACS) sorted using a FACStar cytom-
eter (Becton Dickinson, San Jose, CA). Within the total population of Ly-5
Cychrome cells, 2 populations were sorted: the Gr-1 strongly positive
(CD3-PE and B220-PE cells) and the Gr-1 weakly positive cell fraction
(CD3-PE and B220-PE cells). From both cell suspensions, cytospin
preparations were made using a Cytofuge (Nordic Immunological Labora-
tories, Tilburg, The Netherlands). After drying, the cells were stained with
MGG. Differential counts of the cell preparations were performed. In the
peripheral blood samples, 99% of the Gr-1 strongly positive, CD3 and
B220, cells were mature neutrophils. In the bone marrow samples we
found 93% of this population to be mature neutrophils. The Gr-1 weakly
positive population contained mainly immature neutrophils. Both popula-
tions contained less than 1% monocytes. The same staining procedure as
described above was used, but then fluorescence intensity was analyzed by
flow cytometry (FACStar; Becton Dickinson). On the basis of morphology,
Gr-1 strongly positive cells were regarded as mature neutrophils (Figure 1).
Genotyping
Progeny of CD11a/ mice were genotyped at 6 weeks of age by
polymerase chain reaction amplification of DNA samples from tail tissue.
Presence of the targeted allele was detected by amplification using primers
with sequence (5 to 3): ACCAGTCTCTGCTTCTTCTGCAC (forward)
and sequence (5 to 3): TATCAGGACATAGCGTTGGCTACCC (re-
verse). Amplifications were performed on a GeneAmp PCR system 2400
(Applied Biosystems, Perkin Elmer, Nieuwerkerk a/d IJssel, The Nether-
lands) for 33 cycles with an oligonucleotide annealing temperature of 59°C.
Genotypes of animals were routinely confirmed by FACS analysis of
the peripheral blood samples with an anti-CD11a antibody (clone I21/7;
Caltag Laboratories, Burlingame, CA) as described above.
Detection of circulating and cellbound antibodies
To determine levels of free circulating antibody, plasma was obtained from
mice at various time intervals after a single intraperitoneal injection of 100
g anti–LFA-1 or anti–Mac-1 antibodies. A quantity of 2  105 peripheral
blood leukocytes of untreated mice was then incubated with a volume of 50
L plasma for 30 minutes at 4°C. Cells were washed once and subsequently
labeled with PE-conjugated goat anti-rat IgG (Caltag Laboratories). After
washing, the cells were resuspended in PBS containing 0.8 g/L albumin. To
detect cellbound antibody, peripheral blood leukocytes and bone marrow
cells were obtained from mice treated at various time intervals after a single
injection of anti–LFA-1 or anti–Mac-1 antibody and labeled with PE-
conjugated goat antirat IgG. The fluorescence intensity was analyzed using
a flow cytometer.
Figure 1. Neutrophils in the bone marrow were determined by FACS analysis.
Neutrophils represent the Gr-1 strongly positive population within the Ly5-Cy5 cell
fraction.
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CAFC assay
In vitro determination of HPC frequencies was performed by limited dilution
analysis of cobblestone area–forming cells (CAFCs) in microcultures accord-
ing to the method previously described.35,36 Briefly, cells were seeded on a
preestablished stromal layer of the murine preadipocyte cell line (FBMD-1,
kindly provided by Dr R. E. Ploemacher, Erasmus University, Rotterdam,
The Netherlands). At weekly intervals until day 35 after initiation, cultures
were scored using an inverted microscope for the presence of cobblestone
areas, defined as colonies of immature hematopoietic cells (at least 6 cells
per colony) residing within the preestablished stromal layer. The proportion
of negative wells at each dilution was used in a Poisson-based limiting
dilution analysis to calculate the CAFC frequency.35,37
Experimental design
In all experiments, mice were pretreated with either a single intraperitoneal
injection of neutralizing anti–LFA-1 or anti–Mac-1 antibodies, control
antibodies, or saline. After 24 hours the mice received intraperitoneal
injections of G-CSF at different doses and schedules and during a variable
number of days. LFA-1–deficient mice and wild-type littermate controls
were treated with a daily injection of G-CSF for 5 days. Twenty-four hours
after the last injection of G-CSF, the mice were killed by CO2 asphyxiation
and peripheral blood was obtained by cardiac puncture. The femurs were
removed. Cell suspensions were prepared, and the numbers of HPCs were
assessed according to the described procedures. An MGG staining of the
peripheral blood cells was performed. The Leiden University Medical
Center ethical committee on animal experiments approved of the
experimental protocol.
Statistical analysis
Differences were evaluated using the Student t test. P  .05 was considered
statistically significant. To calculate the CAFC frequency, a Poisson-based
limiting dilution analysis was used.
Results
Effect of anti–LFA-1 and anti–Mac-1 antibodies on mobilization
of progenitor cells induced by G-CSF
BALB/c mice were injected intraperitoneally with a single dose of
100 g neutralizing anti–LFA-1 antibodies or saline followed after
24 hours by daily injections of 5 g G-CSF or saline for 3 days.
Treatment with neutralizing anti–LFA-1 antibody prior to G-CSF
resulted in a significant increase in the number of circulating
CFU-GMs compared with animals treated with G-CSF only
(1417  921 CFUs per milliliter vs 590  513 CFUs per milliliter,
P  .01, Figure 2). The antibody itself had no mobilizing capacity
(Figure 2). Injection of a non-neutralizing anti–LFA-1 antibody or
neutralizing antibody against ICAM-1 did not result in an increase
of the G-CSF–induced mobilization (non-neutralizing anti–LFA-1
antibody plus G-CSF: 219  84 CFUs per milliliter; anti–ICAM-1
antibody plus G-CSF: 262  177 CFUs per milliliter; G-CSF:
590  513 CFUs per milliliter; P not significant; Figure 2). The
enhancement of G-CSF–induced mobilization observed after pre-
treatment with neutralizing anti–LFA-1 antibodies was indepen-
dent of the dose and schedule of G-CSF used (Figure 3). Only in the
animals treated with G-CSF for 1 day after the pretreatment with
the neutralizing anti–LFA-1 antibody, no significant increase in the
number of circulating CFU-GMs was observed compared with
mice treated with G-CSF only (anti–LFA-1 antibody plus G-CSF:
56  36 CFUs per milliliter; G-CSF: 22  20 CFUs per milliliter;
P not significant; Figure 3).
Pretreatment with different doses of neutralizing anti–Mac-1
antibody followed by G-CSF resulted in a similar increase in the
number of peripheral blood progenitor cells as observed after
treatment with anti–LFA-1 antibodies (Figure 4). In contrast to
anti–LFA-1 antibodies, antibodies directed against Mac-1 exhib-
ited modest mobilization when administered alone. Treatment with
the combination of anti–Mac-1 and anti–LFA-1 antibodies prior to
G-CSF did not result in a further enhancement of mobilization than
obtained with either antibody alone (Figure 4).
Effect of anti–LFA-1 and anti–Mac-1 antibodies on cell counts
in peripheral blood and bone marrow
In comparison with G-CSF–treated controls, mice treated with
anti-2 integrin antibodies prior to G-CSF administration exhibited
a trend toward lower white blood cell and neutrophil counts in the
Figure 2. The G-CSF–induced mobilization of progenitor cells is enhanced by
pretreatment with anti–LFA-1 antibodies. Mice were pretreated with a single
injection of 100 g neutralizing anti–LFA-1 (H154.163, n 	 11) or non-neutralizing
anti–LFA-1 (H155.78, n 	 6), or anti–ICAM-1 (YN1/1.7, n 	 3) or saline (n 	 16).
Twenty-four hours later, 5 g G-CSF was started by daily intraperitoneal injections for
3 days. Twenty-four hours after the last injection, mice were killed and blood was
harvested. Results are expressed as mean  SD. *P . 05 as compared with the
saline-pretreated controls.
Figure 3. Synergistic enhancement of G-CSF–induced mobilization of progeni-
tor cells by anti–LFA-1 antibodies is independent of the dose and schedule of
G-CSF. Mice were pretreated with either a single injection of 100 g anti–LFA-1
antibodies (n 	 3-18) or saline intraperitoneally (n 	 3-18). The following days, mice
received a dose of 2.5 or 5 g G-CSF daily intraperitoneally. Twenty-four hours after
the last injection, mice were killed and peripheral blood was harvested. Results are
expressed as mean SD. * P . 05 as compared with the saline-pretreated controls.
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peripheral blood as estimated by MGG staining or FACS analysis.
As reported previously, mice treated with the neutralizing anti–
LFA-1 antibody followed by G-CSF showed a significant decrease
in platelet counts as compared with controls treated with G-CSF
alone (Table 1). This phenomenon was not observed in mice treated
with anti–LFA-1 antibodies followed by G-CSF for 5 days or in
mice treated with anti–Mac-1 antibodies only (data not shown).
In the animals pretreated with the anti–Mac-1 antibody fol-
lowed by injections of saline or G-CSF, the absolute neutrophil
count in the bone marrow was significantly increased when
compared with the G-CSF–treated control mice (anti–Mac-1 plus
G-CSF: 5.9  106  1.8  106 neutrophils per femur; G-CSF:
2.3  106  1.6  106 neutrophils per femur; P  .01; Figure 5).
Effect of pretreatment with antibodies to 2 integrins on
progenitor cells in the bone marrow
No significant differences in the number of CFU-GMs per femur of
animals treated with either G-CSF alone or G-CSF in combination
with antibodies to the 2 integrins were found (data not shown).
Estimation of circulating and cellbound antibodies
LFA-1 staining of bone marrow cells was observed for 96 hours
after a single injection of 100 g neutralizing anti–LFA-1 antibod-
ies. In the peripheral blood, circulating and cellbound antibody
could be detected up to 120 hours after a single injection. Free
circulating antibody was measured up to 48 hours after a single
injection of 100 g anti–Mac-1 antibody. Cellbound antibodies on
peripheral blood and bone marrow cells could be demonstrated for
72 hours after anti–Mac-1 antibody injection.
CAFC assay of peripheral blood and bone marrow
Committed progenitor cells and stem cells in blood and bone
marrow of mice treated with a single injection of anti–LFA-1
antibody followed by G-CSF for 5 days were assessed in a
CFU-GM and CAFC assay. A correlation was found between the
CFU-GM assay and the number of CAFCs on day 7 (data not
shown). The number of CAFCs–day 28 in the peripheral blood of
mice treated with anti–LFA-1 antibody and G-CSF was signifi-
cantly higher compared with mice treated with G-CSF only
(119  34 CAFCs per milliliter vs 17  14 CAFCs per milliliter;
P  .01; Figure 6). The number of CAFCs–day 28 in the bone
marrow was not significantly different between the 3 groups of
mice (saline: 655  333 CFUs per milliliter; G-CSF: 374  153
CFUs per milliliter; anti–LFA-1 antibody plus G-CSF: 472  158
CFUs per milliliter).
Mobilization in LFA-1–deficient mice
The number of circulating CFUs was not increased in LFA-1–
deficient mice when compared with wild-type littermate controls
(57  66 vs 23  21). Treatment with 5 g G-CSF for 5 days did
not reveal a difference in the number of CFU per milliliter of blood
between both groups (LFA-1–deficient: 1694  875 CFUs per
milliliter; wild-type: 1629  748 CFUs per milliliter; Figure 7).
Nor did the LFA-1–deficient mice show a difference in their white
blood cell count, the number of platelets, or the number of
progenitor cells in the bone marrow when compared with their
wild-type littermate controls (data not shown).
Discussion
In this study we found that treatment with neutralizing antibodies to
the 2 integrins LFA-1 and Mac-1 enhances stem cell mobilization
induced by G-CSF administration. The increase in mobilization
was independent of the dose and schedule of G-CSF used but was
Table 1. Effect of treatment with anti–LFA-1 antibodies (–LFA-1)








Saline 8.3  1.7 2.0  0.7 1068  279
Saline
G-CSF 2 d, 2.5 g/d 9.8  2.5 2.8  1.6 738  84

–LFA-1
G-CSF 2 d, 2.5 g/d 9.3  1.7 2.6  0.5 309  58*
Saline
G-CSF 1 d, 5 g/d 13.3  3.5 7.0  2.0 610  367

–LFA-1
G-CSF 1 d, 5 g/d 8.2  1.6 3.3  0.4 281  85*
Saline
G-CSF 2 d, 5 g/d 12.4  3.0 4.6  2.0 936  244

–LFA-1
G-CSF 2 d, 5 g/d 8.9  1.6 3.2  1.8 634  111*
Saline
G-CSF 3 d, 5 g/d 10.5  3.2 3.4  1.1 709  180

–LFA-1
G-CSF 3 d, 5 g/d 8.4  1.8 3.6  1.1 351  313*
Saline
G-CSF 5 d, 5 g/d 19.6  2.8 12.5  2.3 705  89

–LFA-1
G-CSF 5 d, 5 g/d 22.8  6.3 16.3  4.1 922  313
On day 0, mice were treated with a single intraperitoneal injection of 100 g
antibody or saline. Twenty-four hours later, G-CSF was administered as a once-daily
injection. Twenty-four hours after the last injection of G-CSF, mice were killed and
blood was obtained by a cardiac puncture. Results are expressed as meanSD (n	
3-18, 2-3 experiments).
*P .05 compared with the saline-pretreated controls.
Figure 4. The G-CSF–induced mobilization of progenitor cells is synergistically
enhanced by pretreatment with anti–Mac-1 antibodies (5C6). Mice were pre-
treated with a single injection of anti–Mac-1 antibodies intraperitoneally (n 	 5-18) or
saline (n 	 5-18) followed by either 5 g G-CSF per day or saline. The injections
were given once daily for 2 days, starting 24 hours after antibody treatment.
Twenty-four hours after the last injection, mice were killed and blood was harvested.
Results are expressed as mean  SD. *P  .05 compared with the saline plus
G-CSF–treated controls.
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observed only under conditions when G-CSF alone induced
mobilization. It was also observed at a maximal dose of G-CSF,
suggesting the involvement of an additional pathway in the
induction of mobilization. The combination of anti–LFA-1-and
anti–Mac-1 antibodies did not result in further enhancement of
mobilization, indicating that blocking either 2 integrin is suffi-
cient for an optimal effect. The enhancing effect of anti–LFA-1
antibodies was specific, because a non-neutralizing, isotype-
matched control antibody to LFA-1 did not affect mobilization. A
low amount of endotoxin was detected in the anti–Mac-1 antibody.
Although this was insufficient to induce stem cell mobilization, the
possibility cannot be excluded that it contributed to the synergistic
effect. The possibility was considered that the increased mobiliza-
tion reflects a rebound phenomenon after administration of anti–
LFA-1 antibodies. This was unlikely because free circulating
antibody was present for the entire duration of the experiment.
LFA-1–deficient mice did not exhibit enhanced mobilization in
response to G-CSF in comparison with wild-type littermate con-
trols. This may be explained by the lack of activation of a subset of
hematopoietic cells through the absence of the LFA-1 antigen and
inability of antibody binding. Alternatively, the presence of a
redundant pathway that compensates for the loss of the LFA-1
signal cannot be excluded. The pathway is not mediated through
CD11b, because up-regulation of CD11b on the neutrophils of the
LFA-1–deficient mice could not be detected by FACS analysis.
In recent years it has become evident that adhesion molecules
play a role in retaining stem cells in the bone marrow microenviron-
ment. Antibodies to the 1 integrin VLA-4 and its main ligand,
VCAM-1, are capable of mobilizing HPCs in mice and in
primates24,38 whereas, consistent with previous reports, we found
that anti–LFA-1 antibodies have no such capacity.24,30,39 The
observed enhancement of G-CSF–induced mobilization by pretreat-
ment with antibodies to these 2 integrins is not likely mediated
through binding to ICAM-1, because administration of anti–
ICAM-1 antibodies prior to G-CSF did not show an increase in
mobilization. In previous studies we have shown that this anti–
ICAM-1 antibody does inhibit IL-8–induced mobilization.30 This
strongly suggests that the induction of mobilization by the
Figure 5. The number of neutrophils in the femur as assessed by FACS analysis
is increased after pretreatment with anti–Mac-1 antibodies (5C6). Mice were
pretreated with a single injection of anti–Mac-1 antibodies intraperitoneally (n 	 5-
18) or saline (n 	 5-18) followed by either 5 g G-CSF per day or saline. The
injections were given once daily for 2 days, starting 24 hours after antibody treatment.
Twenty-four hours after the last injection, mice were killed and bone marrow was
harvested. Results are expressed as mean  SD. *P  .05 compared with the
G-CSF–treated controls.
Figure 6. The numbers of CAFCs in peripheral blood are increased after
pretreatment with neutralizing anti–LFA-1 antibodies. Mice were treated intraperi-
toneally with saline (n 	 3), G-CSF 5 g/d for 5 days (n 	 9), or anti–LFA-1
antibodies followed by G-CSF during 5 days (n 	 4). Twenty-four hours after the last
injection, blood was obtained by cardiac puncture. Results are expressed as mean
 SD. *P  .05 compared with the G-CSF–treated controls.
Figure 7. The G-CSF–induced mobilization of peripheral blood progenitor cells
is not enhanced in LFA-1 knock-out mice. LFA-1 knock-out mice and their
wild-type littermate controls were either treated with saline (n 	 10 and n 	 11,
respectively) or with 5 g G-CSF once daily for 5 days (n 	 18 and n 	 19,
respectively). Twenty-four hours after the last injection, mice were killed and blood
was obtained by cardiac puncture. Results are expressed as mean SD.
2-INTEGRIN ABs ENHANCE G-CSF–INDUCED MOBILIZATION 331BLOOD, 1 JULY 2002  VOLUME 100, NUMBER 1
anti–LFA-1 monoclonal antibodies is not due to inhibiting the
adhesion of LFA-1 to ICAM-1, but it is more likely due to signaling
processes induced by clustering LFA-1 receptors through antibod-
ies.40,41 The reason that a noninhibitory anti–LFA-1 antibody does
not induce mobilization might be because it less strongly clusters
and induces signaling as it binds to a distinct site on LFA-1 outside
the ligand-binding pocket.
Previously it was found that neutrophils express LFA-1 and
Mac-1 and release gelatinase-B upon activation by IL-8.42-44
Therefore, it was hypothesized that neutrophils play a key role as
accessory cells in mediating IL-8–induced mobilization.28,45 In-
deed, IL-8–induced mobilization was absent in neutropenic mice
and could be restored by administration of neutrophils.45 Neutro-
phils could also fulfill a crucial role in the enhancement of
G-CSF–induced mobilization by anti–LFA-1 and anti–Mac-1 anti-
bodies. Antibodies against the 2 integrins could inhibit adherence
of neutrophils to platelet monolayers and P selectin.46 This may
result in in vivo inhibition of migration through the endothelial wall
into the vascular lumen. We observed an increase in the number of
neutrophils in the bone marrow of mice treated with a combination
of anti–Mac-1 antibodies and G-CSF (Figure 5), supporting a
decreased migration of neutrophils from the bone marrow into the
peripheral blood. Because administration of G-CSF results in
neutrophil activation,47,48 we hypothesize that the increased mobili-
zation observed after administration of antibodies to the 2
integrins prior to G-CSF is related to an increase of activated
neutrophils in the bone marrow.
In accordance, recent studies in mice indicate that proteases
released from neutrophils (ie, neutrophil elastase and cathepsin G)
may be involved in G-CSF–induced stem cell mobilization. In the
plasma of G-CSF–mobilized patients the concentration of VCAM-1
cleavage products was increased, concomitant with a decrease of
VCAM-1 expression in the bone marrow. These results suggest that
G-CSF–induced mobilization is mediated by interruption of the
VCAM-1/VLA-4 pathway,49 through cleaving by neutrophil proteases.
Apart from its role in G-CSF–induced mobilization, the admin-
istration of antibodies to LFA-1 resulted in a significant thrombocy-
topenia. This phenomenon was also observed by Pruijt et al.30
Thrombocytopenia was observed 2 hours after injection, suggest-
ing a direct interaction of the antibody and platelets. In accordance,
CD11a is expressed on the surface of murine platelets.50 In addition
to this, the adhesion of megakaryocytes is an important process in
platelet formation.51 Antibodies to CD18 inhibit the binding of
megakaryocytes to cytokine-stimulated endothelial cells, thereby
interfering with the platelet formation.52
In conclusion, G-CSF–induced stem cell mobilization is syner-
gistically enhanced by a single injection of blocking antibodies to
the 2-integrins LFA-1 and Mac-1. The enhancement is indepen-
dent of the dose and schedule of G-CSF, suggesting the involve-
ment of an additional pathway in mobilization induction. In
LFA-1–deficient mice this phenomenon was not observed. This
indicates that the synergistic effect observed is mediated by cells
expressing LFA-1 that are activated by cross-linking LFA-1 receptors.
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